Clinical Trial: A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07819019) titled 'A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer' on Aug. 14.

Brief Summary: English Translation (for ClinicalTrials.gov Patient-Friendly Summary):

This is a Phase II clinical trial for patients with advanced gastric cancer (stomach cancer). We are looking for participants whose cancer has progressed after one prior standard chemotherapy regimen and whose tumors test positive for the PD-L1 protein.

This study is testing the effectiveness of a combination of three medications:

1. Irinotecan liposome: A chemotherapy drug wrapped in tiny fat particles (li...